SG Americas Securities LLC Purchases 12,259 Shares of Accuray Incorporated (NASDAQ:ARAY)

SG Americas Securities LLC grew its stake in Accuray Incorporated (NASDAQ:ARAY) by 37.4% in the 4th quarter, Holdings Channel.com reports. The fund owned 45,079 shares of the medical equipment provider’s stock after purchasing an additional 12,259 shares during the quarter. SG Americas Securities LLC’s holdings in Accuray were worth $89,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Foundry Partners LLC grew its holdings in shares of Accuray by 51.3% in the 3rd quarter. Foundry Partners LLC now owns 2,187,160 shares of the medical equipment provider’s stock valued at $3,937,000 after acquiring an additional 741,900 shares in the last quarter. State Street Corp grew its holdings in shares of Accuray by 3.8% in the 3rd quarter. State Street Corp now owns 1,894,287 shares of the medical equipment provider’s stock valued at $3,410,000 after acquiring an additional 70,008 shares in the last quarter. Barclays PLC grew its holdings in shares of Accuray by 97.9% in the 3rd quarter. Barclays PLC now owns 210,819 shares of the medical equipment provider’s stock valued at $380,000 after acquiring an additional 104,310 shares in the last quarter. BNP Paribas Financial Markets grew its holdings in shares of Accuray by 1,650.6% in the 3rd quarter. BNP Paribas Financial Markets now owns 146,384 shares of the medical equipment provider’s stock valued at $263,000 after acquiring an additional 138,022 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. grew its holdings in shares of Accuray by 489.1% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 277,859 shares of the medical equipment provider’s stock valued at $500,000 after acquiring an additional 230,695 shares in the last quarter. Institutional investors own 64.08% of the company’s stock.

Accuray Trading Up 2.2 %

Accuray stock opened at $2.28 on Friday. Accuray Incorporated has a 52 week low of $1.40 and a 52 week high of $2.95. The company has a debt-to-equity ratio of 3.51, a quick ratio of 0.87 and a current ratio of 1.62. The stock has a market capitalization of $234.45 million, a P/E ratio of -45.60 and a beta of 1.51. The stock has a 50-day simple moving average of $2.13 and a 200 day simple moving average of $1.98.

Accuray (NASDAQ:ARAY) last posted its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $0.02 EPS for the quarter, topping analysts’ consensus estimates of ($0.01) by $0.03. Accuray had a negative return on equity of 9.75% and a negative net margin of 0.96%. Analysts expect that Accuray Incorporated will post 0.01 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Separately, StockNews.com upgraded Accuray from a “hold” rating to a “buy” rating in a report on Monday.

Accuray Company Profile

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.